Dormant disseminated tumor cells (DTCs) persist despite anti-tumor immunity. How these cells evade immunosurveillance is unknown. Goddard et al. reveal a previously unappreciated form of immunoevasion called “relative scarcity” that underlies DTC persistence. T cell-based immunotherapies increase interaction frequency between DTCs and antigen-specific T cells, leading to DTC depletion.